Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gefitinib Following Chemotherapy in Advanced NSCLC
NCT00091156Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2004
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started May 2004; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00091156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091156.